| dc.creator | Mayer, Kenneth H. | |
| dc.creator | Phanuphak, Nittaya | |
| dc.creator | Mgodi, Nyaradzo | |
| dc.creator | Grinsztejn, Beatriz | |
| dc.date | 2022-07-29T17:38:49Z | |
| dc.date | 2022-07-29T17:38:49Z | |
| dc.date | 2022 | |
| dc.date.accessioned | 2023-09-26T23:49:32Z | |
| dc.date.available | 2023-09-26T23:49:32Z | |
| dc.identifier | MAYER, Kenneth H. et al. New HIV prevention approaches: promise, praxis, and pitfalls. Lancet, v. 400, n. 10348, p. 257-259, 2022 | |
| dc.identifier | 0140-6736 | |
| dc.identifier | https://www.arca.fiocruz.br/handle/icict/54081 | |
| dc.identifier | 10.1016/S0140-6736(22)01351-4 | |
| dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/8894621 | |
| dc.description | More than a decade since the demonstration that
antiretrovirals used for pre-exposure prophylaxis (PrEP)
were safe and effective in decreasing HIV transmission,
these medications remain underused, but continue to
be needed, given the persistent burden of incident HIV
infection, particularly in multiple sub-Saharan African
countries. In 2020, there were about 1,5 million new HIV
infections globally, representing a decline of only 31%
since 2010.
Oral tenofovir-based PrEP is highly effective,
but disparities remain due to lower PrEP uptake and
adherence among populations disproportionately
impacted by HIV. Less than a third of approximately
3 million people who could benefit from PrEP have used
it, with most PrEP users located in affluent countries. | |
| dc.format | application/pdf | |
| dc.language | eng | |
| dc.rights | restricted access | |
| dc.subject | HIV | |
| dc.subject | HIV prevention | |
| dc.subject | HIV Transmission | |
| dc.subject | Pre-exposure prophylaxis (PrEP) | |
| dc.subject | Antiretrovirals | |
| dc.title | New HIV prevention approaches: promise, praxis, and pitfalls | |
| dc.type | Article | |
